Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi 305: tarlatamab + durvalumab versus durvalumab maintenance in extensive-stage small cell lung cancer after platinum-etoposide-durvalumab
2023-505989-29-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Jun 2024
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 30
01
Overview
Phase 3, randomised, open-label trial in small cell lung cancer (SCLC) comparing Tarlatamab + durvalumab with Durvalumab alone (2 arms). Primary endpoint: Overall survival. Planned start Jun 2024; status: authorised.
02
Drugs
tarlatamabdurvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2023-505989-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-505989-29-00.